Published summary: 2026-03-07
Where the evidence converges
Meta-analysis found schizophrenia patients who used cannabis had better cognitive performance than non-using patients, suggesting a different pathway to psychosis
Strong evidence · 22 studies
The meta-analysis included mostly cross-sectional studies. Better cognition in cannabis users could reflect selection bias (more cognitively intact people are more likely to access and use cannabis).
Meta-analysis of 37 studies found one-third of first-episode psychosis patients use cannabis, with regular use typically starting 6
Strong evidence · 22 studies
Observational studies cannot prove causation. Heterogeneity across studies was noted. Recall bias in reporting cannabis use onset age. Different studies defined cannabis use differently. The meta-anal
Meta-analysis of 14 studies found young psychosis patients who currently use cannabis perform worse on IQ, verbal learning, and working memory, except for set-shifting where they excelled
Strong evidence · 22 studies
The studies used varied cognitive assessments, making direct comparison imperfect. The age range (15-45) is broad. Current cannabis use was defined differently across studies. The meta-analysis cannot
Where questions remain
In 232 first-episode schizophrenia patients, cannabis preceded psychosis in one-third, coincided with onset in another third, and began after symptoms in the final third, suggesting multiple pathways
Moderate evidence · 93 studies
Retrospective timing of symptom and drug use onset is subject to recall bias. The three groups are approximate and the boundaries between them may be artificial. The sample included only those who dev
Population-based study of 232 first schizophrenia episodes finding double the rate of substance abuse compared to controls, with cannabis used by 88% of drug abusers and drug use often preceding illness onset
Moderate evidence · 93 studies
The retrospective component relied on patient recall, which may be unreliable especially regarding the timing of first symptoms. The correlation between drug use onset and illness onset does not prove
Population-based study of 133 schizophrenia patients found male cannabis users developed their first psychotic episode 6
Moderate evidence · 93 studies
The cross-sectional design cannot establish causation. Cannabis use was assessed retrospectively, which introduces recall bias. The study cannot determine whether cannabis use precipitated psychosis i
Comprehensive review found strong evidence linking cannabis to psychosis, supported the existence of cannabis withdrawal syndrome, and called for more rigorous research on prevention and treatment
Moderate evidence · 93 studies
As a narrative review, it did not systematically grade the quality of evidence for each claim. The causal direction of the cannabis-mental health relationship was acknowledged as uncertain. Prevention
Research gaps
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
About One-Third of People With Cannabis-Induced Psychosis Later Develop Schizophrenia
Distinguishing cannabis-induced psychosis from the onset of a primary psychotic disorder is one of the most consequential diagnostic challenges in psychiatry. This meta-analysis quantifies the stakes: about a third of cannabis-induced psychosis cases may actually be the first presentation of schizop
Psychological interventions showed minimal benefit for people with both schizophrenia and substance use disorders
About 42% of people with schizophrenia have co-occurring substance use disorders, yet they are frequently excluded from clinical trials. This comprehensive meta-analysis reveals that current evidence-based psychological treatments are essentially ineffective for this doubly burdened population, high
Meta-Analysis Confirms Cannabis Can Cause Paranoid Symptoms
Paranoia is common and has significant social consequences. This meta-analysis provides converging evidence from both experimental (causal) and observational designs that cannabis, particularly THC-dominant products, can cause paranoid symptoms.
Adolescent Cannabinoid Exposure Produced Schizophrenia-Like Behavior Across 359 Animal Experiments
This is the first meta-analysis to comprehensively test whether epidemiological links between adolescent cannabis use and schizophrenia are supported by controlled animal experiments. The consistent findings across hundreds of experiments strengthen the biological plausibility of this association.
Cannabis Use Linked to Suicide Attempts and Death in People With Schizophrenia
Suicide is a leading cause of death in schizophrenia. Identifying cannabis use as a risk factor for suicide attempts and death provides an actionable target for clinical intervention.
Cannabis Use in Schizophrenia: More Positive Symptoms, Fewer Negative Symptoms in Large Meta-Analysis
This is the largest IPDMA on cannabis and schizophrenia symptoms to date. The finding that cannabis use is associated with lower negative symptoms (amotivation, flat affect) alongside higher positive symptoms (hallucinations, delusions) creates a complex picture with implications for treatment.
How the research developed
Pre-2000
1 studies published. Predominantly observational and review studies.
2000–2009
21 studies published. Includes 5 RCTs, 2 strong-evidence studies.
2010–2014
46 studies published. Includes 1 meta-analyses, 7 RCTs, 2 strong-evidence studies.
2015–2019
145 studies published. Includes 6 meta-analyses, 13 RCTs, 22 strong-evidence studies.
2020–present
315 studies published. Includes 12 meta-analyses, 11 RCTs, 71 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 528 peer-reviewed studies: 19 meta-analyses (4%), 36 randomized controlled trials (7%), 142 observational studies (27%), 129 reviews (24%), 28 case studies (5%), 174 other study types (33%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.